Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial

Publication Details

Journal of the American College of Cardiology

August 2026

Access Here

Author(s)

Sarah M Birkhoelzer¹, Yasuhiro Hamatani², Karola S Jering ², Brian Claggett², Muthiah Vaduganathan², Jan M Griffin³, Francesco Cappelli⁴, Olivier Lairez⁵, Julian D Gillmore⁶, Marianna Fontana⁶, Scott D Solomon⁷

Affiliations

¹Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; University Hospitals Dorset, Bournemouth, United Kingdom; ²Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; ³Medical University of South Carolina, Charleston, South Carolina, USA; ⁴Bis Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy; Tuscan Amyloidosis Referral Center Careggi University Hospital, Florence, Italy; ⁵University of Toulouse, Toulouse, France; ⁶National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom; ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA